Home
About
- Company
- Careers
Technology
Pipeline
Collaboration
News
Investors
Contact

Menu

Home
About
- Company
- Careers
Technology
Pipeline
Collaboration
News
Investors
Contact

Search

Close

中文

Menu

中文

Our Vision

Home > Company > Our Vision

Our Vision
Company Profile
Management Team
Journey & Honors

Menu

Our Vision
Company Profile
Management Team
Journey & Honors

We are committed to leading the development of new drugs for the treatment of genitourinary tumors and other major diseases

Links

Company
Technology
Pipeline
Collaboration
News
Careers
Contact

News

Asieris to publish the study protocol of Cevira® as a novel treatment in patients with high grade squamous intraepithelial lesion (HSIL) on BMJ Open
2022 ASCO, Asieris Presented a Study Protocol of Muscle Invasive Bladder Cancer(MIBC)
Asieris to present a study protocol of APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy (NAC) for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting
Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy
Now Hiring: Lab Manager (San Francisco)
Now Hiring: Operations Manager (San Francisco)
Now Hiring: Head of Toxicology, Director to Senior Director (Shanghai or San Francisco)

Contact

info@asieris.com
USA
201 King of Prussia Rd.
Suite 650 Radnor, PA 19087
USA
319 N. Bernardo Ave.
Mountain View, CA 94043
China
8F Building 56
1000 Jinhai Rd
Pudong, Shanghai

Join Us

Partner with us

Copyright © 2014-2022 Asieris Pharmaceuticals. All Rights Reserved.